Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events

被引:45
作者
Verma, Sumita [1 ]
Ajudia, Ketan [1 ]
Mendler, Michel [1 ]
Redeker, Allan [1 ]
机构
[1] Univ So Calif, Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA
关键词
alcoholic hepatitis; cirrhosis; septic event; hepatorenal syndrome; short-term mortality; discriminant function; MELD score;
D O I
10.1007/s10620-006-9099-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We sought to assess prevalence, and utility of discriminant function (DF) and MELD score in predicting septic events (SE), type 1 hepatorenal syndrome (HRS), and short-term mortality in severe alcoholic hepatitis (AH). Charts of patients with AH (group 1) and cirrhosis without AH (group 2) were retrospectively reviewed. Severe AH, discriminant function (DF) >= 32 was treated with pentoxifylline. One hundred ninety-five patients were enrolled in the study and divided into 2 groups: group 1, n=99, and group 2, n=96. Of those with AH, 82% had a DF >= 32 at presentation. Group 1 patients had a higher prevalence of SE (38% versus 25%, P=.04), type 1 HRS (30% versus 9%, P=.0003), and short-term mortality (28% versus 7%, P=.0001). In patients with AH, a MELD score >= 20 (but not a DF >= 32) at presentation was an independent predictor of a SE (odds ratio [OR] 2.8 [1.0-7.9], P=.04), HRS (OR 4.0, 95% confidence interval [CI] 1.0-16.6, P=0.05), and short-term mortality (OR 6.4, 95% CI 1.1-37.6, P=.03). Kaplan-Meier survival curves confirmed that that a MELD >= 20 but not a DF >= 32 was associated with a poorer survival (P = .005 and .5, respectively). In conclusion, patients with severe AH have higher prevalence of SE, HRS, and short-term mortality compared to those with cirrhosis without AH. A MELD score >= 20 at presentation is an independent predictor of these adverse events in patients with AH who have been treated with pentoxifylline.
引用
收藏
页码:1637 / 1643
页数:7
相关论文
共 29 条
[1]
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial [J].
Akriviadis, E ;
Botla, R ;
Briggs, W ;
Han, S ;
Reynolds, T ;
Shakil, O .
GASTROENTEROLOGY, 2000, 119 (06) :1637-1648
[2]
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[3]
LIVER SCINTISCANNING AS A SCREENING-TEST IN THE DETECTION OF ALCOHOLIC CIRRHOSIS [J].
BAUDOUIN, SV ;
GREY, H ;
HALLCRAGGS, M ;
WELLS, CP ;
RAKE, MO ;
COAKLEY, AJ .
NUCLEAR MEDICINE COMMUNICATIONS, 1986, 7 (01) :71-75
[4]
IN-VITRO AND IN-VIVO STUDIES OF CELLULAR IMMUNITY IN ALCOHOLIC CIRRHOSIS [J].
BERENYI, MR ;
STRAUS, B ;
CRUZ, D .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1974, 19 (03) :199-205
[5]
Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition:: A multicenter randomized trial [J].
Cabré, E ;
Rodríguez-Iglesias, P ;
Caballería, J ;
Quer, JC ;
Sánchez-Lombraña, JL ;
Parés, A ;
Papo, M ;
Planas, R ;
Gassull, MA .
HEPATOLOGY, 2000, 32 (01) :36-42
[6]
CAITHERS RL, 1989, ANN INTERN MED, V110, P685
[7]
A PROSPECTIVE-STUDY OF BACTERIAL-INFECTIONS IN PATIENTS WITH CIRRHOSIS [J].
CALY, WR ;
STRAUSS, E .
JOURNAL OF HEPATOLOGY, 1993, 18 (03) :353-358
[8]
GLUCOCORTICOIDS ARE INEFFECTIVE IN ALCOHOLIC HEPATITIS - A METAANALYSIS ADJUSTING FOR CONFOUNDING VARIABLES [J].
CHRISTENSEN, E ;
GLUUD, C .
GUT, 1995, 37 (01) :113-118
[9]
Deschênes M, 1999, AM J GASTROENTEROL, V94, P2193, DOI 10.1016/S0002-9270(99)00349-4
[10]
MELD accurately predicts mortality in patients with alcoholic hepatitis [J].
Dunn, W ;
Jamil, LH ;
Brown, LS ;
Wiesner, RH ;
Kim, WR ;
Menon, KVN ;
Malinchoc, M ;
Kamath, PS ;
Shah, V .
HEPATOLOGY, 2005, 41 (02) :353-358